

FLUoxetine

- Drug Information

Brand Names:

PROzac®, Reconcile™ (Not available 2016), Sarafem®

Pharmacology:

Phenylpropylamine derivative antidepressant.
Selective serotonin reuptake inhibitor.

Indications:

May be used in the treatment of behavioral disorders in small animals. Possibly in the treatment of phobias, stereotypic and obsessive compulsive disorders.

Recent approval of Reconcile - chewable product labeled for use in dogs for the treatment of separation anxiety in conjunction with a behavior modification plan.

Contraindications:

- General

Contraindicated in patients with known sensitivity to this type of drug.

Concurrent use of MAO inhibitors is contraindicated and may result in serious side effects.

Discontinue FLUoxetine 5 weeks prior to MAOI administration and discontinue MAOI 14 days prior to FLUoxetine administration.

Contraindicated in diabetes mellitus, in patients with prior seizure disorders / epilepsy and should not be given with other drugs that may lower the seizure threshold.

Caution with patients with liver disease-may need lower doses.

Use only when benefit outweighs the risk during pregnancy as safety has not been established.

Safe use of Reconcile™ beyond 8 weeks of therapy has not been established - professional judgment should be used in monitoring the patient's response to therapy to determine the need to continue treatment with Reconcile™ beyond 8 weeks.

Reconcile™ is not recommended for the treatment of canine aggression.

For dogs taking Reconcile™ - it is recommended they be greater than 6 months of age and greater than 8.8 pounds.

Interactions:

- General Interactions

May enhance the effects of lithium, haloperidol and L-tryptophan.

- Category Interactions

- MAOI - Monoamine Oxidase Inhibitor

Concurrent use may result in serious side effects. Discontinue FLUoxetine 5 weeks prior to MAOI administration and discontinue MAOI 14 days prior to FLUoxetine administration.

- Phenothiazine

Reconcile™ should not be given with drugs that lower the seizure threshold.

- Protein bound drug

May displace other highly protein bound drugs resulting in increased activity of both.

- TCA - Tricyclic Antidepressant

May enhance the effects of TCAs.

- Drug Interactions

- BusPIRone

May enhance the effects of BusPIRone.

- ClomiPRAMINE

Metabolism of ClomiPRAMINE may be inhibited by FLUoxetine and result in cardiac conduction disturbances in humans.

- Cyproheptadine

May decrease or reverse the effects of SSRI drugs.

- Diazepam

May enhance the effects of diazepam.

- MetroNIDAZOLE

Enhanced extrapyramidal (tremors) are possible.

Adverse Effects:**- General**

Possible side effects include anxiety, agitation, seizures, weight loss, lethargy, panting, aggression, nervousness, shaking, shivering, tremors, insomnia, drowsiness, dizziness, sweating, anorexia, nausea, diarrhea and vomiting.

Dosages:**- General**

It is important to combine behavior modification techniques with drug therapy for maximum efficacy. For specific information regarding diagnosis, treatment and prognosis regarding specific behavior disorders, refer to specific reference material.

Clients should be cautioned that the veterinary version of these products are formulated to be palatable to pets. This can increase the likelihood for inadvertent overdose of the medication if the container is not stored with this in mind.

- Small Animal**- Dog**

0.5 - 1 mg/kg by mouth once to twice daily.

Reconcile™ : 1 - 2 mg/kg administered once daily.

- Cat

0.5 - 1 mg/kg by mouth every 24 hours

Special Notes:

None